Inserm 2015 Host Laboratories and Research Programs

1. Francois Tronche

Role of Brahma and BRG1 Chromatin Remodelers in Behavioral Responses to Drugs of Abuse

Clinical and preclinical research strongly suggests that the stress response is a key determinant in the appearance of addiction. Stress release of glucocorticoids activates their receptor (GR). We demonstrated that GR gene inactivation in dopaminceptive neurons was sufficient to strongly reduce behavioral responses to psychostimulant (Ambroggi et al Nat Neurosci. 2009, Barik et al. Biol Psychiatry 2010) and to block the development of social aversion following repeated aggressions (Barik et al. Science 2013).

Refine anatomical dissection of GR gene functions. To dissociate the effects of GR gene inactivation in the PFC from the effects of its inactivation in the NAcc, we will generate mice deprived of GR in either one or the other of these structures, using viral delivery of the Cre recombinase.

Understand epigenetic mechanisms underlying GR function. GR controls gene expression in part by recruiting chromatin remodeler complexes containing brahma or BRG1 that shape the chromatin and may be responsible for long-lasting changes in gene expression. We established mouse lines deprived of Brm, BRG1, and both proteins in dopaminceptive neurons. Their behavior will be compared to that of GR mutants in order to reveal whether the interaction of Brm and BRG1 with GR sustains responses to cocaine.

Contact: Francois Tronche, Group Leader Gene Regulation and Adaptive Behaviors, francois.tronche@upmc.fr

Laboratory: Equipe Gene Regulation and Adaptive Behaviors, Neuroscience Paris-Seine
INSERM UMR51130, Institut de Biologie Paris-Seine, 7 quai Saint Bernard, Bat B, 2e étage, case courrier 002, 75 252 Paris CEDEX 05, France
Tel: 33 6 63 14 12 36

2. Marie-Odile Krebs

Stress and Cannabis: Crossed Vulnerability During Adolescence to Long Lasting Cognitive and Behavioral Impairments in Adult

Contact: Marie-Odile Krebs, marie-odile.krebs@inserm.fr

Laboratory: Laboratoire de Physiopathologie de Maladies psychiatriques, Centre de Psychiatrie et Neurosciences, Service Hospitalo Universitaire, Centre Hospitalier Sainte-Anne, 75014 Paris
Tel: 01 45 65 86 46
Fax: 01 45 65 81 60
Additional Email: s.pottin@ch-sainte-anne.fr
3., 4., and 5. Jean-Paul Moatti

**Epidemiology and Social Sciences in the Field of Addictions**

**Project 3:** An epidemiological study enrolling a cohort of 800 injecting drug users with a 12-month follow-up and 3-month interval interviews to assess the impact of individual and structural factors on health and risky behaviors.

**Project 4:** A pharmacological study to assess the effective dose of methylphenidate (MPH) in cocaine-dependent individuals using a combination of socio-behavioral and pharmacokinetic approaches preliminarily to a randomized clinical trial to evaluate the efficacy of MPH for cocaine dependence.

**Project 5:** A clinical trial assessing the efficacy of intravenous buprenorphine for opioid-dependent individuals who have failed with oral opioid substitution treatment.

**Contact:** Pérrine Roux, perrine.roux@inserm.fr

**Laboratory:** SESSTIM, INSERM UMR912-INSERM/IRD, Address: UMR912, 23 rue Stanislas Torrents, 13006 Marseille, France
Tel: 33 0496102876
Fax: 33 0496102899

6. Marcello Solinas

**Role of Cognitive Training on Cocaine Self-Administration in Rats**

Exposure to environmental enrichment (EE) produces profound positive effects on drug addiction. EE is comprised of different types of stimulation including social interaction, physical activity and cognitive stimulation. In this project, we will investigate whether cognitive stimulation by itself can also be beneficial in animal models of addiction. Our working hypothesis is that training rats in cognitive tasks that require inhibitory control prior to self-administration session will reduce both active drug taking and risks of relapse. We will use operant cognitive tasks that we have developed in our laboratory and self-intravenous administration of drugs. In addition, provided that positive results are obtained we will use molecular techniques to investigate the neurobiological mechanisms involved.

**Contact:** Marcello Solinas, marcello.solinas@univ-poitiers.fr

**Laboratory:** INSERM Unit: U1084, INSERM Team: Neurobiology and Neuropharmacology of addiction
Tel: 33 5 49 36 63 43
7. Laurence Lanfumey

**Ethanol and Epigenetic Regulations in the Mouse Brain**

We have recently shown that chronic and moderate ethanol intake could regulate cell proliferation in adult C57BL/6J mouse hippocampus. This effect involved chromatin remodeling and BDNF over-expression associated with an increase in transcriptional activity due to an inhibition of HDACs (histone deacetylases) expression and a hypomethylation of the main CpG islands present within the BDNF gene. Interestingly, while neurogenesis is known to influence hippocampus-dependent learning and memory, we showed that the epigenetic-induced increase in neuroplasticity factors after ethanol intake did not increase hippocampal LTP. However, memory-related behaviors were affected by ethanol (Stragier et al. 2015, and submitted). In order to further characterize the effects of ethanol, we propose to use novel pharmacological tools, targeting either epigenetic enzymes, or BDNF/TrkB complex to dissect the effect of ethanol.

**Contact:** Laurence Lanfumey, laurence.lanfumey@inserm.fr

**Laboratory:** Centre de Psychiatrie et Neurosciences, INSERM UMR 894, 2ter rue d’Alesia, 75014 Paris

8. Mickael Naassila

**Looking for a Marker of Alcohol Addiction: Is Loss of Phasic Dopamine Release and Synaptic Plasticity Critical?**

The objectives of this proposal are to determine the neural substrates of the alcohol addiction process and especially the changes in phasic dopamine release and synaptic plasticity that may represent the keystone by which alcohol hijacks reward circuits and leads to an overlearning of cues predicting drug availability. Identifying this keystone action of alcohol also targets phasic dopamine release as potential therapeutic intervention. The present project is aimed at elucidating the neurobiological bases of alcohol addiction using relevant preclinical models of alcohol addiction (using the inhalation procedure to induce both physical and psychological dependence) and the technical approaches such as *in vivo* electrochemical (fast cyclic voltammetry) and *ex vivo* electrophysiological recording techniques.

**Contact:** Mickael Naassila, mickael.naassila@inserm.fr

**Laboratory:** INSERM Unit ERi 24 – Research Group on Alcohol & Pharmacodependences (GRAP), Université de picardie Jules Verne, Amiens, France
9. Jocelyne Caboche

**Epigenetic Regulation in Addiction: Role of miR128b**

Addiction is a chronic disease characterized by a loss of control over use and compulsive drug taking, in spite of adverse effects on health and psychological state. It is now well established that this pathology relies on neuroadaptative processes in specific brain areas: the “reward circuitry”. This project will study the molecular mechanisms that underlie cocaine-induced neuroadaptation in the striatum, with a particular emphasis of the short non-coding RNA: miR128b. We will collaborate with Dr. Anne Schaefer (anne.schaefer@mssm.edu), Assistant Professor at Icahn School of Medicine at Mount Sinai in New York, who generated a transgenic mouse that can overexpress miR128b. This miRNA controls the neuronal excitability and locomotor activity (Tan et al., 2013). miR128b will be overexpressed in striatal neurons expressing D1 receptors specifically. We will study in these mice cocaine-induced long-term behavioral responses (locomotor sensitization, conditioned place preference). Post-mortem, on striatal slices, we will study intracellular signaling pathways (MAPkinase/ERK; Elk-1 CREB) and gene regulation induced by cocaine. This study will provide new therapeutic avenues in addiction. Tan et al., (2013) MicroRNA-128 governs neuronal excitability and motor behavior in mice. Science. Dec 6; 342(6163):1254-8.

**Contact:** Jocelyne Caboche, Jocelyne.caboche@upmc.fr

**Laboratory:** Neurosciences Paris Seine, INSERM U 1130, CNRS UMR 8246, UPMC UM 119. Université Pierre et Marie Curie 7-9 quai Saint Bernard, Bat A, B 75252 Paris, CEDEX 05

10. Jean-Louis Laplanche, Bruno Mégarbane

**Addiction Properties of the New Synthetic Cathinones: A Behavioral and Molecular Approach**

The use of synthetic cathinones in the recreational scene is exponentially spreading. However, only limited experimental data support their potential for abuse. The objective of this project is to investigate the addictive potential of different cathinones in comparison to cocaine and amphetamine in a rodent model of addiction and study their involvement on dopamine in reward-related behaviors through the mesolimbic dopaminergic pathway using an *in vivo* microdialysis approach. The contribution of different monoamines and specific transporters at the blood-brain barrier will be studied. In this proposal, we will combine behavioral, neurochemical and pharmacokinetic approaches after acute and repeated administration, to better understand the mechanisms involved in cathinone abuse.

**Contact:** Bruno Mégarbane, bruno.megarbane@lrb.aphp.fr

**Laboratory:** Inserm UMR-S 1144, Universités Paris Descartes – Paris Diderot Variabilité de Réponse aux Psychotropes – Response Variability to Psychotropics Faculté de Pharmacie de Paris, 4 avenue de l’observatoire, 75006 Paris, France
Tel: 33 1 53 73 96 34
Fax: 33 1 40 51 75 60
Assistant Email: ariane.tersac@inserm.fr
Website: [http://www.umrs1144.com/](http://www.umrs1144.com/)
11. Jean-Louis Laplanche, Frank Bellivier

**Mutation Screening, Genetic Association and Gene-Gene Interaction Modeling Studies in Addiction**

Our research team is involved in clinical phenotyping and biological sampling of cohorts of drugs of abuse users (mainly cocaine and opiates). We use a variety of approaches such as transcriptional profiling, molecular genetics and genome-wide epigenetics in combination with extensive clinical characterization to study vulnerability factors to addictions as well as factors influencing illness course. Ongoing projects on cocaine addiction include next-generation sequencing of a large cohort of cocaine addicts and controls, targeting a pathway possibly involved in cocaine dependence according to pre-clinical studies. In addition, an SNP-based gene association study is ongoing in patients with complex addiction (poly-dependence) regarding subjective effects of first cocaine use. The objective of the project is to establish gene association and gene-gene interaction modeling studies in addiction based on a large and complex set of data.

**Contact:** Frank Bellivier, frank.bellivier@inserm.fr

**Laboratory:** Inserm UMR-S 1144, Universités Paris Descartes – Paris Diderot Variabilité de Réponse aux Psychotropes – Response Variability to Psychotropics
Faculté de Pharmacie de Paris, 4 avenue de l'observatoire, 75006 Paris, France
Tel: 33 1 53 73 96 34
Fax: 33 1 40 51 75 60
Assistant Email: ariane.tersac@inserm.fr
Website: [http://www.umrs1144.com/](http://www.umrs1144.com/)

12. Jean-Luc Martinot

**Outcome of Cannabis and Other Addictions: Multidisciplinary Database of Adolescents**

Substances of abuse such as cannabis have deleterious effects on the brain maturation at adolescence that can be tackled by multimodal MR imaging techniques acquired in the context of an international cohort. Participants were assessed for psychometry, neuropsychology, and GWAS, and their parents completed questionnaires. INSERM Unit 100 is a partner in this unique resource database that includes multidisciplinary data from >2000 14 year-old adolescents who were followed up. Outcome data at ages 16 and 18 might be available for analysis.

Raising specific hypotheses on the relationships between these brain images and psychobehavioral or genetic data, and performing the analyses would be part of the research exchange. This might be of interest for further French–U.S. collaboration as regards brain imaging and bioinformatics applied to addiction.

**Contact:** Jean-Luc Martinot, jean-luc.martinot@inserm.fr

**Laboratory:** INSERM UNIT 1000, Service Hospitalier Frédéric Joliot, 4 Place du Général Leclerc, 91401 Orsay